US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Kailera Therapeutics (KLRA): Strong Appetite Fuels Kailera IPO Surge, Opens with Ten Point Premium

Kailera Therapeutics (KLRA): Post-180-Day Review: Heavyweight Backers, Lightweight Returns

Kailera Therapeutics (KLRA): Peeking at the IPO Prospectus of a Neurological Therapy Biotech

Kailera Therapeutics (KLRA):Phase III Obesity Biotech Sets Terms with Backing from Bain, QIA

IPOs and Secondary Offerings

Equity Capital Markets

Kailera Therapeutics / Equity Capital Markets

<ul>
<li>Kailera Therapeutics IPO demand is multiple-times oversubscribed, signaling strong institutional interest and potential pricing strength ahead of its expected Friday debut.</li>
<li>Lead asset ribupatide in Phase 3 targets best-in-class weight loss, supported by a diversified GLP-1 pipeline spanning oral and injectable therapies.</li>
<li>Backed by top-tier investors and led by a proven CEO with major biotech exits, positioning the company for strong execution and potential long-term value creation.</li>
</ul>


Kailera Therapeutics IPO demand is multiple-times oversubscribed, signaling strong institutional interest and potential pricing strength ahead of its expected Friday debut.
Lead asset ribupatide in Phase 3 targets best-in-class weight loss, supported by a diversified GLP-1 pipeline spanning oral and injectable therapies.
Backed by top-tier investors and led by a proven CEO with major biotech exits, positioning the company for strong execution and potential long-term value creation.


Kailera Therapeutics (KLRA): Bain Backed Obesity Biotech Garners Significant Interest